Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 936

1.

Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis.

Fermont JM, Masconi KL, Jensen MT, Ferrari R, Di Lorenzo VAP, Marott JM, Schuetz P, Watz H, Waschki B, Müllerova H, Polkey MI, Wilkinson IB, Wood AM.

Thorax. 2019 Jan 7. pii: thoraxjnl-2018-211855. doi: 10.1136/thoraxjnl-2018-211855. [Epub ahead of print]

2.

[The stepwise approach of COPD therapy].

Watz H, Kirsten A, Greulich T.

Dtsch Med Wochenschr. 2019 Jan;144(1):15-20. doi: 10.1055/a-0570-3595. Epub 2019 Jan 2. German.

PMID:
30602182
3.

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.

Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 6;13:3923-3936. doi: 10.2147/COPD.S179293. eCollection 2018.

4.

Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial.

Watz H, Tetzlaff K, Magnussen H, Mueller A, Rodriguez-Roisin R, Wouters EFM, Vogelmeier C, Calverley PMA.

Respir Res. 2018 Dec 13;19(1):251. doi: 10.1186/s12931-018-0944-3.

5.

Economic burden of bronchiectasis in Germany.

Diel R, Chalmers JD, Rabe KF, Nienhaus A, Loddenkemper R, Ringshausen FC.

Eur Respir J. 2018 Dec 5. pii: 1802033. doi: 10.1183/13993003.02033-2018. [Epub ahead of print]

PMID:
30523162
6.

New Biologics for Severe Asthma: What Patients, What Agents, What Results, at What Cost?

Rabe KF.

Am J Respir Crit Care Med. 2018 Nov 8. doi: 10.1164/rccm.201810-1974ED. [Epub ahead of print] No abstract available.

PMID:
30407843
7.

[Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology].

Buhl R, Bals R, Baur X, Berdel D, Criée CP, Gappa M, Gillissen A, Greulich T, Haidl P, Hamelmann E, Kardos P, Kenn K, Klimek L, Korn S, Lommatzsch M, Magnussen H, Nicolai T, Nowak D, Pfaar O, Rabe KF, Riedler J, Ritz T, Schultz K, Schuster A, Spindler T, Taube C, Taube K, Vogelmeier C, von Leupoldt A, Wantke F, Weise S, Wildhaber J, Worth H, Zacharasiewicz A.

Pneumologie. 2017 Dec;71(12):e3. doi: 10.1055/a-0790-0021. Epub 2018 Nov 7. German. No abstract available.

PMID:
30406626
8.

Correction to: The all age asthma cohort (ALLIANCE) - from early beginnings to chronic disease: a longitudinal cohort study.

Fuchs O, Bahmer T, Weckmann M, Dittrich AM, Schaub B, Rösler B, Happle C, Brinkmann F, Ricklefs I, König IR, Watz H, Rabe KF, Kopp MV, Hansen G, von Mutius E; ALLIANCE Study Group as part of the German Centre for Lung Research (DZL).

BMC Pulm Med. 2018 Nov 7;18(1):165. doi: 10.1186/s12890-018-0717-2.

9.

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort.

Greulich T, Mager S, Lucke T, Koczulla AR, Bals R, Fähndrich S, Jörres RA, Alter P, Kirsten A, Vogelmeier CF, Watz H.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 28;13:2999-3002. doi: 10.2147/COPD.S165909. eCollection 2018. No abstract available.

10.

Cardiovascular disease and COPD: dangerous liaisons?

Rabe KF, Hurst JR, Suissa S.

Eur Respir Rev. 2018 Oct 3;27(149). pii: 180057. doi: 10.1183/16000617.0057-2018. Print 2018 Sep 30. Review. Erratum in: Eur Respir Rev. 2018 Nov 21;27(150):.

11.

Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.

Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C.

Lancet Respir Med. 2018 Oct;6(10):747-758. doi: 10.1016/S2213-2600(18)30327-8. Epub 2018 Sep 16. Erratum in: Lancet Respir Med. 2018 Oct 4;:.

PMID:
30232048
12.

Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.

Rabe KF, Watz H, Baraldo S, Pedersen F, Biondini D, Bagul N, Hanauer G, Göhring UM, Purkayastha D, Román J, Alagappan VKT, Saetta M.

Lancet Respir Med. 2018 Nov;6(11):827-836. doi: 10.1016/S2213-2600(18)30331-X. Epub 2018 Sep 14. Erratum in: Lancet Respir Med. 2018 Oct 12;:.

PMID:
30224319
13.

Influence of body mass on predicted values of static hyperinflation in COPD.

Alter P, Rabe KF, Schulz H, Vogelmeier CF, Jörres RA.

Int J Chron Obstruct Pulmon Dis. 2018 Aug 23;13:2551-2555. doi: 10.2147/COPD.S164096. eCollection 2018.

14.

Inhaled corticosteroids in COPD: friend or foe?

Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FME, Rabe KF, Papi A.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801219. doi: 10.1183/13993003.01219-2018. Print 2018 Dec. Review.

PMID:
30190269
15.

Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD.

Lazaar AL, Miller BE, Tabberer M, Yonchuk J, Leidy N, Ambery C, Bloomer J, Watz H, Tal-Singer R.

Eur Respir J. 2018 Oct 4;52(4). pii: 1801020. doi: 10.1183/13993003.01020-2018. Print 2018 Oct. No abstract available.

PMID:
30139779
16.

The all age asthma cohort (ALLIANCE) - from early beginnings to chronic disease: a longitudinal cohort study.

Fuchs O, Bahmer T, Weckmann M, Dittrich AM, Schaub B, Rösler B, Happle C, Brinkmann F, Ricklefs I, König IR, Watz H, Rabe KF, Kopp MV, Hansen G, von Mutius E; ALLIANCE Study Group as part of the German Centre for Lung Research (DZL).

BMC Pulm Med. 2018 Aug 20;18(1):140. doi: 10.1186/s12890-018-0705-6. Erratum in: BMC Pulm Med. 2018 Nov 7;18(1):165.

17.

Identification of novel target genes in human lung tissue involved in chronic obstructive pulmonary disease.

Heinbockel L, Marwitz S, Schromm AB, Watz H, Kugler C, Ammerpohl O, Schnepf K, Rabe KF, Droemann D, Goldmann T.

Int J Chron Obstruct Pulmon Dis. 2018 Jul 26;13:2255-2259. doi: 10.2147/COPD.S161958. eCollection 2018.

18.

[Perspectives for the Electroencephalogram in Psychiatry].

Kirsten A, Linder S, Olbrich S.

Praxis (Bern 1994). 2018 Jul;107(15):837-843. doi: 10.1024/1661-8157/a003028. Review. German.

PMID:
30043707
19.

Human alveolar epithelial cells type II are capable of TGFβ-dependent epithelial-mesenchymal-transition and collagen-synthesis.

Goldmann T, Zissel G, Watz H, Drömann D, Reck M, Kugler C, Rabe KF, Marwitz S.

Respir Res. 2018 Jul 24;19(1):138. doi: 10.1186/s12931-018-0841-9.

20.

Fountain of youth for squamous cell carcinomas? On the epigenetic age of non-small cell lung cancer and corresponding tumor-free lung tissues.

Marwitz S, Heinbockel L, Scheufele S, Kugler C, Reck M, Rabe KF, Perner S, Goldmann T, Ammerpohl O.

Int J Cancer. 2018 Dec 15;143(12):3061-3070. doi: 10.1002/ijc.31641. Epub 2018 Oct 16.

Supplemental Content

Loading ...
Support Center